Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. TIXTAR (rifaximine), anti-infectieux intestinal
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

TIXTAR (rifaximine), anti-infectieux intestinal

Medicine - Posted on May 21 2025
Active substance (DCI)
  • rifaximine
history (3)
  • 4/23/25

    TIXTAR (rifaximine) - Encéphalopathie hépatique

    Réévaluation à la demande de la CT / sur saisine ministérielle L'essentiel Avis favorable au maintien du remboursement uniqu...
    CAV :
    54321
    icône flèche
  • 6/23/21

    TIXTAR (rifaximine)

    Key points Favourable opinion for reimbursement only in the prevention of recurrence of episodes of breakthrough overt hepat...
    CAV :
    54321
    icône flèche
  • 11/18/15

    TIXTAR (rifaximin), intestinal anti-infective agent

    Minor improvement in the prevention of relapse of episodes of recurrent clinical hepatic encephalopathy with at least 2 prio...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • A07AA11
Manufacturer
ALFASIGMA FRANCE
Presentation

TIXTAR 550 mg, comprimé pelliculé (code CIS : 63467355)
plaquette(s) PVC polyéthylène PVDC aluminium de 56 comprimé(s) (CIP : 34009 300 096 6 6)

All our publications
    Central nervous system diseases Drug therapy Liver diseases Metabolic diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
hgbas9tWDcTCg9kd